Role of in silico genotoxicity tools in the regulatory assessment of pharmaceutical impurities

References

• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline Impurities in new Drug Substances Q3A(R2), 2006. Available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Guideline.pdf
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline Impurities in new Drug Products Q3B(R2), 2006. Available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2__Guideline.pdf
   Google Scholar
• Roy , A , Nyarady , S and Matchett , M . 2009 . Genotoxic and non-genotoxic impurities in pharmaceuticals. Current regulations, status and trend . Chimica Oggi , 27 : 19 – 23 .
   Web of Science ®Google Scholar
• Serafimova , R , Gatnik , MFuart and Worth , A . 2010 . Review of QSAR Models and Software Tools for Predicting Genotoxicity and Carcinogenicity , EUR 24427 EN : European Commission Joint Research Centre Report . Available at http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/14330/1/jrc%20report_genotoxicity%20qsar.pdf
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline Impurities for Residual Solvents, ICH Q3C (R4), 2009. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002674.pdf
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use, S2 (R1), 2008. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074931.pdf
   Google Scholar
• Tweats , D . 2010 . Future approaches for genotoxicity testing of drugs and impurities . Toxicol. Lett. , 196 : S11 – S14 .
   Web of Science ®Google Scholar
• Guideline on the limits of genotoxic impurities CPMP/SWP/5199/02; EMA/CHMP/QWP/251344/2006. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002903.pdf
   Google Scholar
• Barlow , SM , Kozianowski , G , Wurtzen , G and Schlatter , J . 2001 . Threshold of toxicological concern for chemical substances in the diet . Food Chem. Toxicol. , 39 : 893 – 905 .
   PubMedGoogle Scholar
• Kroes , R , Renwick , AG , Cheeseman , M , Kleiner , J , Mangelsdorf , I , Piersma , A , Schilter , B , Schlatter , J , van Schothorst , F , Vos , JG and Würtzen , G . 2004 . Structure-based thresholds of toxicological concern (TTC): Guidance for application to substances present at low levels in the diet . Food Chem. Toxicol. , 42 : 65 – 83 .
   PubMed Web of Science ®Google Scholar
• Munro , IC , Kennepohl , E and Kroes , R . 1999 . A procedure for safety evaluation of flavouring substances . Food Chem. Toxicol. , 37 : 207 – 232 .
   PubMed Web of Science ®Google Scholar
• Snodin , D . 2009 . Genotoxic impurities in drug substances . Org. Process Res. Dev. , 13 : 409 – 409 .
   Web of Science ®Google Scholar
• Müller , L , Mauthe , RJ , Riley , CM , Andino , MM , Antonis , DD , Beels , C , DeGeorge , J , De Knaep , AGM , Ellison , D , Fagerland , JA , Frank , R , Fritschel , B , Galloway , S , Harpur , E , Humfrey , CDN , Jacks , AS , Jagota , N , Mackinnon , J , Mohan , G , Ness , DK , O'Donovan , MR , Smith , MD , Vudathala , G and Yotti , L . 2006 . A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity . Reg. Toxicol. Pharmacol. , 44 : 198 – 211 .
   PubMed Web of Science ®Google Scholar
• CDER (FDA) (2008), Guidance for Industry. Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079235.pdf
   Google Scholar
• EMA/CHMP/SWP/431994/2007, Questions & Answers on the CHMP Guideline on the Limits of Genotoxic Impurities. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002907.pdf
   Google Scholar
• Miller , EC and Miller , JA . 1981 . Mechanisms of chemical carcinogenesis . Cancer , 47(S1) : 1055 – 1064 .
   Web of Science ®Google Scholar
• Benigni , R and Bossa , C . 2008 . Structure alerts for carcinogenicity, and the Salmonella assay system: A novel insight through the chemical relational databases technology . Mutat. Res. Rev. Mutat. Res. , 659 : 248 – 261 .
   PubMed Web of Science ®Google Scholar
• Enoch , SJ and Cronin , MTD . 2010 . A review of the electrophilic reaction chemistry involved in covalent DNA binding . Crit. Rev. Toxicol. , 40 : 728 – 748 .
   PubMed Web of Science ®Google Scholar
• Bailey , AB , Chanderbhan , R , Collazo-Braier , N , Cheeseman , MA and Twaroski , ML . 2005 . The use of structure-activity relationship analysis in the food contact notification program . Reg. Toxicol. Pharmacol. , 42 : 225 – 235 .
   PubMed Web of Science ®Google Scholar
• Kazius , J , McGuire , R and Bursi , R . 2005 . Derivation and validation of toxicophores for mutagenicity prediction . J. Med. Chem. , 48 : 312 – 320 .
   PubMed Web of Science ®Google Scholar
• Munro , IC , Ford , RA , Kennepohl , E and Sprenger , JG . 1996 . Thresholds of toxicological concern based on structure-activity relationships . Drug Metab. Rev. , 28 : 209 – 217 .
   PubMed Web of Science ®Google Scholar
• Ashby , J and Tennant , RW . 1988 . Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTP . Mutat. Res. Genet. Toxicol. , 204 : 17 – 115 .
   PubMed Web of Science ®Google Scholar
• Ashby , J . 1985 . Fundamental structural alerts to potential carcinogenicity or noncarcinogenicity . Environ. Mutagen. , 7 : 919 – 921 .
   PubMedGoogle Scholar
• Matthews , EJ , Kruhlak , NL , Benz , RD , Contrera , JF , Marchant , CA and Yang , C . 2008 . Combined Use of MC4PC, MDL-QSAR, BioEpisteme, Leadscope PDM, and Derek for Windows software to achieve high-performance, high-confidence, mode of action-based predictions of chemical carcinogenesis in rodents . Toxicol. Mech. Method. , 18 : 189 – 206 .
   PubMed Web of Science ®Google Scholar
• Contrera , JF , Matthews , EJ and Benz , RD . 2001 . Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices . Reg. Toxicol. Pharmacol. , 38 : 243 – 259 .
   Web of Science ®Google Scholar
• Benz , RD . 2007 . Toxicological and clinical computational analysis and the US FDA/CDER . Expert Opin. Drug. Metab. Toxicol. , 3 : 109 – 124 .
   PubMed Web of Science ®Google Scholar
• Matthews , EJ and Contrera , JF . 2007 . In silico approaches to explore toxicity end points: Issues and concerns for estimating human health effects . Expert Opin. Drug. Metab. Toxicol. , 3 : 125 – 134 .
   PubMed Web of Science ®Google Scholar
• Gombar , VK , Mattioni , BE , Zwickl , C and Deahl , JT . 2006 . Computational approaches for assessment of toxicity: A historical perspective and current status . Comp. Toxicol. , : 183 – 215 .
   Google Scholar
• Klopman , G . 1984 . Artificial intelligence approach to structure-activity studies. Computer automated structure evaluation of biological activity of organic molecules . J. Am. Chem. Soc. , 106 : 7315 – 7321 .
   Web of Science ®Google Scholar
• Klopman , G . 1992 . MULTICASE 1. A hierarchical computer automated structure evaluation program . QSAR , 11 : 176 – 184 .
   Web of Science ®Google Scholar
• Molconn-Z, released by eduSoft. Available at http://www.edusoft-lc.com/molconn/
   Google Scholar
• Valerio , LJ and Long , A . 2010 . The in silico prediction of human-specific metabolites from hepatotoxic drugs . Curr. Drug Disc. Technol. , 7 : 170 – 187 .
   PubMedGoogle Scholar
• Contrera , JF , Matthews , EJ , Kruhlak , NL and Benz , RD . 2005 . In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software . Reg. Toxicol. Pharmacol. , 43 : 313 – 323 .
   PubMed Web of Science ®Google Scholar
• Sazonovasa , A , Japertasa , P and Didziapetrisa , R . 2010 . Estimation of reliability of predictions and model applicability domain evaluation in the analysis of acute toxicity (LD50) . SAR QSAR Environ Res. , 21 : 127 – 148 .
   PubMed Web of Science ®Google Scholar
• Didziapetris , R , Lanevskij , K and Japertas , P . 2008 . Trainable QSAR model of Ames genotoxicity . Toxicol Lett. , 180 : S152 – S153 .
   Web of Science ®Google Scholar
• Bentzien , Jr , Hickey , ER , Kemper , RA , Brewer , ML , Dyek , JD , East , SP and Whittaker , M . 2010 . An in silico method for predicting Ames activities of primary aromatic amines by calculating the stabilities of nitrenium ions . J. Chem. Inf. Model. , 50 : 274 – 297 .
   PubMed Web of Science ®Google Scholar
• Bercu , JP , Morton , SM , Deahl , JT , Gombar , VK , Callis , CM and van Lier , RBL . 2010 . In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances . Reg. Toxicol. Pharmacol. , 57 : 300 – 306 .
   PubMed Web of Science ®Google Scholar
• Contrera , JF . 2010 . Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities . Reg. Toxicol. Pharmacol. , 9 : 133 – 141 .
   Google Scholar
• Pérez-Garrido , A , Helguera , AM , López , GC , Cordeiro , MNDS and Escudero , AG . 2010 . A topological substructural molecular design approach for predicting mutagenesis end-points of [alpha], [beta]-unsaturated carbonyl compounds . Toxicol. , 268 : 64 – 77 .
   PubMed Web of Science ®Google Scholar
• Pfuhler , S , Kirst , A , Aardema , M , Banduhn , N , Goebel , C , Araki , D , Costabel-Farkas , M , Dufour , E , Fautz , R , Harvey , J , Hewitt , NJ , Hibatallah , J , Carmichael , P , Macfarlane , M , Reisinger , K , Rowland , J , Schellauf , F , Schepky , A and Scheel , J . 2010 . A tiered approach to the use of alternatives to animal testing for the safety assessment of cosmetics: Genotoxicity. A COLIPA analysis . Reg. Toxicol. Pharmacol. , 57 : 315 – 324 .
   PubMed Web of Science ®Google Scholar
• Prabu , S and Suriyaprakash , T . 2010 . Impurities and its importance in pharmacy . Int. J. Pharm. Sci. Rev. Res. , 3 : 66 – 71 .
   Google Scholar
• Rao , N , Kiran , S and Prasanthi , N . 2010 . Pharmaceutical impurities: An overview . Indian J. Pharm. Educ. Res. , 44 : 301 – 310 .
   Web of Science ®Google Scholar
• Robinson , DI . 2010 . Control of genotoxic impurities in active pharmaceutical ingredients: A review and perspective . Org. Process Res. Dev. , 14 : 946 – 959 .
   Web of Science ®Google Scholar
• Snodin , DJ . 2010 . Genotoxic impurities: From structural alerts to qualification . Org. Process Res. Dev. , 14 : 960 – 976 .
   Web of Science ®Google Scholar
• Sushko , I , Novotarskyi , S , Körner , R , Pandey , AK , Kovalishyn , VV , Prokopenko , VV and Tetko , IV . 2010 . Applicability domain for in silico models to achieve accuracy of experimental measurements . J. Chemom. , 24 : 202 – 208 .
   Web of Science ®Google Scholar
• Callis , CM , Bercu , JP , DeVries , KM , Dow , LK , Robbins , DK and Varie , DL . 2010 . Risk assessment of genotoxic impurities in marketed compounds administered over a short-term duration: Applications to oncology products and implications for impurity control limits . Org. Process Res. Dev. , 14 : 986 – 992 .
   Web of Science ®Google Scholar
• Thayer , A . 2010 . Genotoxic impurities . Chem. Eng. News , 88 : 16 – 26 .
   Web of Science ®Google Scholar
• Worth , A , Lapenna , S , Piparo , ELo , Mostrag-Szlichtyng , A and Serafimova , R . The applicability of software tools for genotoxicity and carcinogenicity prediction: case studies relevant to the assessment of pesticides, European Commission Joint Research Centre Report, EUR 24640 EN, 2010
   Google Scholar
• Frid , AA and Matthews , EJ . 2009 . Prediction of drug-related cardiac adverse effects in humans-B: Use of QSAR programs for early detection of drug-induced cardiac toxicities . Regul. Toxicol. Pharmacol. , 56 : 276 – 289 .
   PubMed Web of Science ®Google Scholar
• Hansen , K , Mika , S , Schroeter , T , Sutter , A , ter Laak , A , Steger-Hartmann , T , Heinrich , N and Muller , KR . 2009 . Benchmark data set for in silico prediction of Ames mutagenicity . J. Chem. Inf. Model. , 49(9) : 2077 – 2081 .
   Web of Science ®Google Scholar
• Rothenbacher , T and Schwack , W . 2009 . Nontargeted multicomponent analytical screening of plastic food contact materials using fast interpretation of deliverables via expert structure-activity relationship software . J AOAC Int. , 92 : 941 – 950 .
   PubMed Web of Science ®Google Scholar
• Roy , A , Nyarady , S and Matchett , M . 2009 . Genotoxic and non-genotoxic impurities in pharmaceuticals. Current regulations, status and trend . Chimica Oggi/Chemistry Today , 27 : 19 – 23 .
   Web of Science ®Google Scholar
• Snodin , D and Vudathala , G . 2009 . Genotoxic impurities: A case for a regulatory rethink . American Association of Pharmaceutical Scientists (AAPS) News Magazine , : 20 – 27 .
   Google Scholar
• Snyder , RD . 2009 . An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity . Environ. Mol. Mutag. , 50 : 435 – 450 .
   PubMed Web of Science ®Google Scholar
• Venkatapathya , R , Wang , CY , Bruce , RM and Moudgal , C . 2009 . Development of quantitative structure–activity relationship (QSAR) models to predict the carcinogenic potency of chemicals: I. Alternative toxicity measures as an estimator of carcinogenic potency . Toxicol. Appl. Pharmacol. , 234 : 209 – 221 .
   PubMed Web of Science ®Google Scholar
• Benigni , R and Bossa , C . 2008 . Predictivity of QSAR . J. Chem. Inf. Model. , 48 : 971 – 980 .
   PubMed Web of Science ®Google Scholar
• Benigni , R and Bossa , C . 2008 . Predictivity and reliability of QSAR models: The case of mutagens and carcinogens . Toxicol. Mech. Method. , 18 : 137 – 147 .
   PubMed Web of Science ®Google Scholar
• Benigni , R , Bossa , C , Richard , A and Yang , C . 2008 . A novel approach: Chemical relational databases, and the role of the ISSCAN database on assessing chemical carcinogenicity . Ann. Ist. Super Sanita. , 44 : 48 – 56 .
   PubMed Web of Science ®Google Scholar
• Contrera , JF , Matthews , EJ , Kruhlak , NL and Benz , RD . 2008 . In silico screening of chemicals for genetic toxicity using MDL-QSAR, nonparametric discriminant analysis, E-state, connectivity, and molecular property descriptors . Toxicol. Mech. Method. , 18 : 207 – 216 .
   PubMed Web of Science ®Google Scholar
• Cotterill , JV , Chaudhry , MQ , Matthews , W and Watkins , RW . 2008 . In silico assessment of toxicity of heat-generated food contaminants . Food Chem. Toxicol. , 46 : 1905 – 1918 .
   PubMed Web of Science ®Google Scholar
• Custer , LL and Sweder , KS . 2008 . The role of genetic toxicology in drug discovery and optimization . Curr. Drug Metab. , 9 : 978 – 985 .
   PubMed Web of Science ®Google Scholar
• Kulkarni , S and Zhu , J . 2008 . Integrated approach to assess the domain of applicability of some commercial (Q)SAR models . SAR QSAR Environ. Res. , 19 : 39 – 54 .
   PubMed Web of Science ®Google Scholar
• Mayer , J , Cheeseman , MA and Twaroski , ML . 2008 . Structure-activity relationship analysis tools: Validation and applicability in predicting carcinogen . Reg. Toxicol. Pharmacol. , 50 : 50 – 58 .
   PubMed Web of Science ®Google Scholar
• Yang , C , Hasselgren , CH , Boyer , S , Arvidson , K , Aveston , S , Dierkes , P , Benigni , R , Benz , RD , Contrera , J , Kruhlak , NL , Matthews , EJ , Han , X , Jaworska , J , Kemper , RA , Rathman , JF and Richard , AM . 2008 . Understanding genetic toxicity through data mining: The process of building knowledge by integrating multiple genetic toxicity database . Toxicol. Mech. Method. , 18 : 277 – 295 .
   PubMed Web of Science ®Google Scholar
• Benigni , R , Netzeva , TI , Benfenati , E , Bossa , C , Franke , R , Helma , C , Hulzebos , E , Marchant , C , Richard , A , Woo , YT and Yang , C . 2007 . The expanding role of predictive toxicology: An update on the (Q)SAR models for mutagens and carcinogens . J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. , 25 : 53 – 97 .
   PubMed Web of Science ®Google Scholar
• Contrera , JF , Kruhlak , NL , Matthews , EJ and Benz , RD . 2007 . Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models . Reg. Toxicol. Pharmacol. , 49 : 172 – 182 .
   PubMed Web of Science ®Google Scholar
• Kruhlak , NL , Contrera , JF , Benz , RD and Matthews , EJ . 2007 . Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products . Adv. Drug Deliv. Rev. , 59 : 43 – 55 .
   PubMed Web of Science ®Google Scholar
• Kulkarni , SA , Moir , D and Zhu , J . 2007 . Influence of structural and functional modifications of selected genotoxic carcinogens on metabolism and mutagenicity – a review . SAR QSAR Environ. Res. , 18 : 459 – 514 .
   PubMed Web of Science ®Google Scholar
• Mazzatorta , P , Tran , L , Schilter , B and Grigorov , M . 2006 . Integration of structure-activity relationship and artificial intelligence systems to improve in silico prediction of Ames test mutagenicity . J. Chem. Inf. Model. , 47 : 34 – 38 .
   Web of Science ®Google Scholar
• Benigni , R and Bossa , C . 2006 . Structure-activity models of chemical carcinogens: State of the art, and new directions . Ann. Ist. Super Sanita. , 42 : 118 – 126 .
   PubMedGoogle Scholar
• Dobo , KL , Greene , N , Cyr , MO , Caron , S and Ku , WW . 2006 . The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development . Reg. Toxicol. Pharmacol. , 44 : 282 – 293 .
   PubMed Web of Science ®Google Scholar
• Snyder , RD , Ewing , D and Hendry , LB . 2006 . DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays . Mutat. Res. Genet. Toxicol. Environ. Mutagen. , 609 : 47 – 59 .
   PubMed Web of Science ®Google Scholar
• Veith , G . 2006 . Roles for QSAR in risk assessment . ALTEX - Alternativen zu Tierexperimenten , 23 Supplement : 369 – 372 .
   Google Scholar
• Benigni , R . 2005 . Structure-activity relationship studies of chemical mutagens and carcinogens: A mechanistic investigations and prediction approaches . Chem. Rev. , 105 : 1767 – 1800 .
   PubMed Web of Science ®Google Scholar
• Crettaz , P and Benigni , R . 2005 . Prediction of the rodent carcinogenicity of 60 pesticides by the DEREK for Windows expert system . J. Chem. Inf. Model. , 45 : 1864 – 1873 .
   PubMed Web of Science ®Google Scholar
• Hall , LH and Hall , LM . 2005 . QSAR modeling based on structure-information for properties of interest in human health . SAR QSAR Environ. Res. , 16 : 13 – 41 .
   PubMed Web of Science ®Google Scholar
• Hayashi , M , Kamata , E , Hirose , A , Takahashi , M , Morita , T and Ema , M . 2005 . In silico assessment of chemical mutagenesis in comparison with results of Salmonella microsome assay on 909 chemicals . Mutat. Res. Genet. Toxicol. Environ. Mutagen. , 588 : 129 – 135 .
   PubMed Web of Science ®Google Scholar
• Helguera , AM , Perez , MC , Combes , RD and Gonzalez , MP . 2005 . The prediction of carcinogenicity from molecular structure . Curr. Comput. Aided Drug Des. , 1 : 237 – 255 .
   Web of Science ®Google Scholar
• Honrao , M . Impurity profile: a review, Pharm. Rev. 3 (2005)
   Google Scholar
• Hulzebos , E , Sijm , D , Traas , T , Posthumus , R and Maslankiewicz , L . 2005 . Validity and validation of expert (Q)SAR systems . SAR QSAR Environ. Res. , 16 : 385 – 401 .
   PubMed Web of Science ®Google Scholar
• Jacobs , A . 2005 . Prediction of 2-year carcinogenicity study results for pharmaceutical products: How are we doing? . Toxicol. Sci. , 88 : 18 – 23 .
   PubMed Web of Science ®Google Scholar
• Snyder , RD and Hendry , LB . 2005 . Toward a greater appreciation of noncovalent chemical/DNA interactions: Application of biological and computational approaches . Environ. Mol. Mutag. , 45 : 100 – 105 .
   PubMed Web of Science ®Google Scholar
• Snyder , RD and Smith , MD . 2005 . Computational prediction of genotoxicity: Room for improvement . Drug Disc. Today , 10 : 1119 – 1124 .
   PubMed Web of Science ®Google Scholar
• Serafimova , R , Todorov , M , Pavlov , T , Kotov , S , Jacob , E , Aptula , A and Mekenyan , O . 2007 . Identification of the structural requirements for mutagenicity, by incorporating molecular flexibility and metabolic activation of chemicals. ii. general Ames mutagenicity model . Chem. Res. Toxicol. , 20 : 662 – 676 .
   PubMed Web of Science ®Google Scholar
• Jacobson-Kram , D and Contrera , JF . 2007 . Genetic toxicity assessment: Employing the best science for human safety evaluation part i: Early screening for potential human mutagens . Toxicol. Sci. , 96 : 16 – 20 .
   PubMed Web of Science ®Google Scholar
• McGovern , T and Jacobson-Kram , D . 2006 . Regulation of genotoxic and carcinogenic impurities in drug substances and products . Trends Anal. Chem. , 25 : 790 – 795 .
   Web of Science ®Google Scholar
• Müller , L , Mauthe , RJ , Riley , CM , Andino , MM , Antonis , DD , Beels , C , DeGeorge , J , Knaep , AGMDe , Ellison , D , Fagerland , JA , Frank , R , Fritschel , B , Galloway , S , Harpur , E , Humfrey , CDN , Jacks , AS , Jagota , N , Mackinnon , J , Mohan , G , Ness , DK , O'Donovan , MR , Smith , MD , Vudathala , G and Yotti , L . A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity, Reg. Toxicol. Pharmacol. 44 (2006), pp. 198–211
   Google Scholar